Related Experiment Video

Updated: Oct 8, 2025

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis
11:44

Analysis of Combinatorial miRNA Treatments to Regulate Cell Cycle and Angiogenesis

Published on: March 30, 2019

7.7K

MiRNAs as Anti-Angiogenic Adjuvant Therapy in Cancer: Synopsis and Potential

Behnaz Lahooti1, Sagun Poudel2, Constantinos M Mikelis1,3

  • 1Department of Pharmaceutical Sciences, School of Pharmacy, Texas Tech University Health Sciences Center, Amarillo, TX, United States.

Frontiers in Oncology
|December 27, 2021
PubMed

Insights

MicroRNAs (miRNAs) offer a novel approach to target tumor angiogenesis, a critical process in cancer growth and metastasis. Evaluating specific miRNAs could lead to more effective adjuvant therapies with fewer side effects.

Area of Science:

  • Oncology
  • Molecular Biology
  • Biochemistry

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for tumor growth, metastasis, and survival.
  • Current anti-angiogenic therapies offer clinical benefits but are associated with significant side effects.
  • MicroRNAs (miRNAs) are key regulators of gene expression, and their dysregulation is implicated in tumor progression and angiogenesis.

Purpose of the Study:

  • To review current anti-angiogenic strategies and their molecular targets.
  • To discuss the role of miRNAs in tumor-induced angiogenesis.
  • To explore the potential of specific miRNAs as anti-angiogenic targets in cancer therapy.

Main Methods:

  • Literature review of current anti-angiogenic approaches.
  • Analysis of existing research on miRNA involvement in angiogenesis.
  • Identification of specific miRNAs with activity on endothelial or cancer cells.

Main Results:

  • Current angiogenesis inhibitors have limitations and side effects.
  • miRNA dysregulation is linked to tumor progression and angiogenesis.
  • Specific miRNAs show potential for anti-angiogenic targeting.

Conclusions:

  • miRNAs represent a promising avenue for developing novel anti-angiogenic therapies.
  • Targeting specific miRNAs could enhance anti-cancer treatments as adjuvant therapy.
  • Further evaluation of angiogenesis in combinatorial approaches is essential.
Keywords:
adjuvant therapyangiogenesiscombinatorialdrugsmiRNAs

More Related Videos

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases09:48

Monitoring of Nanodrug Accumulation in Murine Breast Cancer Metastases

Published on: August 23, 2024

527
Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy09:40

Characterization of Functionally Associated miRNAs in Glioblastoma and their Engineering into Artificial Clusters for Gene Therapy

Published on: October 4, 2019

5.8K

Related Concept Videos

MicroRNAs01:22

MicroRNAs

MicroRNA (miRNA) are short, regulatory RNA transcribed from introns (non-coding regions of a gene) or intergenic regions (stretches of DNA present between genes). Several processing steps are required to form biologically active, mature miRNA. The initial transcript, called primary miRNA (pri-mRNA), base-pairs with itself, forming a stem-loop structure. Within the nucleus, an endonuclease enzyme, called Drosha, shortens the stem-loop structure into hairpin-shaped pre-miRNA. After the pre-miRNA...
3.2K
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the...
17.2K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.9K
Experimental RNAi02:15

Experimental RNAi

RNA interference (RNAi) is a cellular mechanism that inhibits gene expression by suppressing its transcription or activating the RNA degradation process. The mechanism was discovered by Andrew Fire and Craig Mello in 1998 in plants. Today, it is observed in almost all eukaryotes, including protozoa, flies, nematodes, insects, parasites, and mammals. This precise cellular mechanism of gene silencing has been developed into a technique that provides an efficient way to identify and determine the...
6.4K
Regulation of Angiogenesis and Blood Supply01:24

Regulation of Angiogenesis and Blood Supply

Rapidly dividing tumors, embryos, and wounded tissues require more oxygen than usual, lowering the oxygen concentration in the blood. At low oxygen or hypoxic conditions, an oxygen-sensitive transcription factor called the hypoxia-inducible factor 1 or HIF1 is activated. HIF1 is a dimeric protein of alpha (ɑ) and beta (β) subunits.  Under optimal oxygen conditions, HIF1β is present in the nucleus while HIF1ɑ remains in the cytosol. HIF1ɑ is hydroxylated by prolyl...
2.8K